

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on June 2, 2006.

PATENT
Attorney Docket No.: 082368-008200US
Client Reference No.: E1-A0310P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Aaron Hokamura/
Aaron Hokamura

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kenzo MURAMOTO et al.

Application No.:

Int'l Application No.: PCT/JP04/14857

Int'l Filing Date: October 7, 2004

For: PREVENTIVE OR THERAPEUTIC
AGENTS FOR MULTIPLE SCLEROSIS

Confirmation No.:

Examiner:

Art Unit:

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AA - AI are not supplied, in compliance with the provisions of 37 CFR §1.98(a)(2). Copies of references AJ - AR are filed concurrently herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

References AJ and AL-AO were cited in the International Search Report in a corresponding application. A copy of the Search Report is attached.

References AJ and AL-AO are not in the English Language. Reference AJ was categorized as a "Y" document on the enclosed search report. References AL and AN were both

categorized as "A" documents on the enclosed search report. References AM and AO were both categorized as "X" documents on the enclosed search report.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ath
60787610 v1

Substitute for form 1449A&B/PTO				Complete if Known	
				<i>Int'l Application Number</i>	PCT/JP2004/014857
				<i>Int'l Filing Date</i>	October 7, 2004
				<i>First Named Inventor</i>	Muramoto, Kenzo
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
Sheet	1	of	2	Attorney Docket Number	082368-008200US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2002/0161001 A1	10-31-2002	Kanstrup et al.	
	AB	2002/0198205 A1	12-26-2002	Himmelsbach et al.	
	AC	2004/0082570 A1	04-29-2004	Yoshikawa et al.	
	AD	2004/0097510 A1	05-20-2004	Himmelsbach et al.	
	AE	2004/0116328 A1	06-17-2004	Yoshikawa et al.	
	AF	2004/0122228 A1	06-24-2004	Maier et al.	
	AG	2004/0166125 A1	08-26-2004	Himmelsbach et al.	
	AH	2005/0020574 A1	01-27-2005	Hauel et al.	
	AI	2006/0063787 A1	03-23-2006	Yoshikawa et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)			
	AJ	WO	99/12546	A1	03-18-1999	Kyowa Hakko Kogyo Co., Ltd.
	AK	WO	03/104229	A1	12-18-2003	Eisai Co., Ltd.
	AL	JP	10-507171	A	07-14-1998	Chiroscience Ltd.
	AM	JP	2001-114782	A	04-24-2001	Pfizer Inc.
	AN	JP	2001-525413	A	12-11-2001	AstraZeneca AB
	AO	JP	2003-508398	A	03-04-2003	Vanderbilt University

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	AP	REINHOLD, Dirk et al.; "Dipeptidyl peptidase IV (DPIV, CD26) in T cell activation and multiple sclerosis"; International Conference on Dipeptidyl Aminopeptidases, Berlin, September 26-28, 2002; p. 38				<input type="checkbox"/>
	AQ	STEINBRECHER, Andreas et al. "Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-β1 secretion in vivo"; The Journal of Immunology 166:2041-2048 (2001)				<input type="checkbox"/>
Examiner Signature						Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
				<i>Int'l Application Number</i>	PCT/JP2004/014857
				<i>Int'l Filing Date</i>	October 7, 2004
				<i>First Named Inventor</i>	Muramoto, Kenzo
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
Sheet	2	of	2	Attorney Docket Number	082368-008200US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AR	SWANBORG, Robert H.; "Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease"; <u>Clinical Immunology and Immunopathology</u> 77(1):4-13 (October 1995)			<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.